6,109 Shares in Verona Pharma plc (NASDAQ:VRNA) Bought by Personal CFO Solutions LLC

Personal CFO Solutions LLC acquired a new position in shares of Verona Pharma plc (NASDAQ:VRNA - Free Report) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 6,109 shares of the company's stock, valued at approximately $284,000.

Several other large investors have also recently bought and sold shares of the company. GAMMA Investing LLC boosted its holdings in Verona Pharma by 20.7% during the fourth quarter. GAMMA Investing LLC now owns 1,612 shares of the company's stock worth $75,000 after purchasing an additional 276 shares during the last quarter. EMC Capital Management grew its holdings in shares of Verona Pharma by 3,400.0% in the 4th quarter. EMC Capital Management now owns 3,500 shares of the company's stock valued at $163,000 after acquiring an additional 3,400 shares in the last quarter. Wrapmanager Inc. acquired a new stake in shares of Verona Pharma in the fourth quarter valued at about $207,000. Claro Advisors LLC bought a new stake in Verona Pharma during the third quarter worth about $209,000. Finally, Sanctuary Advisors LLC acquired a new position in Verona Pharma during the third quarter valued at approximately $219,000. Institutional investors own 85.88% of the company's stock.

Wall Street Analysts Forecast Growth

VRNA has been the subject of a number of research reports. Roth Capital set a $83.00 price target on Verona Pharma in a research note on Friday, February 28th. HC Wainwright increased their target price on shares of Verona Pharma from $60.00 to $75.00 and gave the stock a "buy" rating in a report on Friday, February 28th. Wells Fargo & Company upped their price objective on shares of Verona Pharma from $74.00 to $93.00 and gave the stock an "overweight" rating in a research report on Friday, February 28th. Roth Mkm started coverage on shares of Verona Pharma in a research report on Friday, January 10th. They issued a "buy" rating and a $68.00 target price on the stock. Finally, Canaccord Genuity Group boosted their target price on shares of Verona Pharma from $44.00 to $72.00 and gave the stock a "buy" rating in a research note on Wednesday, February 12th. Six investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat, the company has an average rating of "Buy" and a consensus price target of $69.14.

Remove Ads

Verona Pharma Stock Up 8.3 %

Verona Pharma stock traded up $5.18 during mid-day trading on Wednesday, reaching $67.88. The stock had a trading volume of 884,466 shares, compared to its average volume of 1,529,003. Verona Pharma plc has a fifty-two week low of $11.39 and a fifty-two week high of $70.40. The firm has a market capitalization of $5.49 billion, a PE ratio of -35.32 and a beta of 0.39. The stock's 50-day simple moving average is $57.72 and its 200-day simple moving average is $43.03. The company has a debt-to-equity ratio of 0.93, a quick ratio of 12.88 and a current ratio of 13.03.

About Verona Pharma

Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis.